9/10/2023 0 Comments Scar in eye retina![]() Those images revealed, according to the study data, that 14.3% (n = 68) developed fibrotic scarring in the first year of the study. Photographic images, according to Daniel, were available for 474 subjects at all 3 (1-, 2-, and 5-year) follow up visits. Classic CNV, Daniel noted, was associated with a 4.5-fold risk (aHR, 4.49 95% CI, 3.34-6.04 P1 disk area) at baseline had nearly double the risk of scarring (aHR, 2.28 95% CI, 1.49-3.47 P < 0.001) in comparison to eyes with no hemorrhages associated with the CNV. Demographic and health data was also collected to determine any additional candidate risk factors for scar formation.ĭaniel and colleagues reported that there were several baseline characteristics that were associated with the development of fibroid scarring during the 5 year study. Daniel and colleagues report that 647 of the 914 patients still living opted to participate in the study which used CFP, FA, and OCT to assess disease progression, morphology, and measure changes in scarring during the CATT and five-year follow up. Throughout the CATT researchers collected patient data via color fundus photographs (CFPs), fluorescein angiogram (FA), and optical coherence tomography (OCT) imaging. During the CATT study patients were randomly assigned to anti-VEGF treatment at 3 dosing regimens for either ranibizumab or bevacizumab. Patients enrolled in the CATT had been diagnosed with CNV associated with AMD and those patients with non-foveal scars on less than half of CNV lesions were included in the original trial. ![]() The CATT took place between February 2008 and December 2009, and according to Daniel was designed to “assess the differences between ranibizumab and bevacizumab, as well as differences between monthly and pro re nata dosing." In addition to recording the development of and changes to fibroid scarring over a five-year period in AMD patients, the study also determined several baseline factors associated with increased risk of fibrotic scarring during anti-VEGF treatment for AMD.ĭata on the 1185 AMD patients with untreated active choroidal neovascularization (CNV) associated with AMD were gathered from a five-year follow up study of patients enrolled in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). ![]() These findings shed light on the long-term outcomes of patients treated with anti-VEGF therapy in a real-world setting beyond clinical trials, said study lead author Ebenezer Daniel, MBBS, PhD, with the Scheie Eye Institute, University of Pennsylvania. A 43-center, prospective cohort study designed to identify and describe risk factors for fibrotic scar formation and fibrotic scar changes in age-related macular degeneration (AMD) patients has determined that there is an increased risk of developing fibrotic scars in the first 2 years of anti-vascular endothelial growth factor (anti-VEGF) treatment, but that risk of scar development decreased after 2 years.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |